Microbot Medical’s LIBERTY Endovascular Robotic System Earns Surgical Robotics Industry Award
Microbot Medical has been recognized with the Innovative Start-Up Award at the 2026 Surgical Robotics Industry Awards, highlighting the company’s achievements in developing groundbreaking robotic technology for minimally invasive vascular procedures. The honor recognizes the growing commercial and technological impact of the company’s LIBERTY® Endovascular Robotic System, the only U.S. Food and Drug Administration (FDA)-cleared, single-use, remotely operated robotic platform designed specifically for peripheral endovascular interventions.
Presented by Surgical Robotics Technology (SRT) in collaboration with QNX, the award celebrates organizations that have demonstrated exceptional innovation while advancing technologies capable of transforming healthcare. For Microbot Medical, the recognition represents another milestone in the company’s mission to redefine robotic-assisted vascular intervention through accessible, efficient, and clinically focused technology.
The award also comes during a period of increasing commercial momentum for the LIBERTY System, which has experienced growing adoption across leading academic medical centers in the United States following its full commercial launch earlier this year.
Recognition for Innovation in Surgical Robotics
The Surgical Robotics Industry Awards recognize companies, technologies, researchers, and healthcare innovators making meaningful contributions to the rapidly evolving field of robotic-assisted surgery.
The Innovative Start-Up Award specifically honors organizations that have achieved notable progress through disruptive technologies capable of reshaping clinical practice while addressing unmet healthcare needs.
Microbot Medical earned the distinction because of its continued development of robotic solutions that simplify endovascular procedures while improving physician workflow and expanding access to advanced robotic intervention.
The award reflects both the technological uniqueness of the LIBERTY platform and the company’s growing commercial success following FDA clearance and market introduction.
Industry recognition of this nature often serves as an important validation of a company’s innovation strategy, particularly within the competitive surgical robotics market where technological differentiation remains a key driver of adoption.
Introducing the LIBERTY Endovascular Robotic System
At the center of Microbot Medical’s recognition is the LIBERTY Endovascular Robotic System, an innovative robotic platform developed specifically for peripheral vascular interventions.
Unlike conventional robotic surgical systems that frequently require large installations and reusable robotic components, LIBERTY introduces a unique design centered on portability, remote operation, and single-use functionality.
The system enables physicians to remotely control guidewires, catheters, and other endovascular devices during minimally invasive vascular procedures.
Designed to provide precise navigation within blood vessels, the robotic platform assists physicians performing complex interventions while potentially improving procedural consistency and operator ergonomics.
Most notably, LIBERTY remains the only FDA-cleared single-use remotely operated robotic system approved for peripheral endovascular procedures in the United States.
This distinction establishes the platform as a new category within surgical robotics focused specifically on minimally invasive vascular intervention.
Transforming Endovascular Procedures
Peripheral endovascular procedures involve navigating medical devices through blood vessels to diagnose or treat vascular disease without requiring open surgery.
These procedures are commonly performed to manage conditions including:
- Peripheral artery disease (PAD)
- Vascular blockages
- Narrowed arteries
- Blood flow disorders
- Other peripheral vascular conditions
Traditionally, physicians manually manipulate guidewires and catheters while standing beside fluoroscopy equipment that continuously produces X-ray images during the intervention.
Although minimally invasive, these procedures often require physicians to wear heavy lead protective equipment while remaining exposed to low levels of radiation throughout lengthy cases.
Microbot Medical developed the LIBERTY platform to address several of these long-standing procedural challenges.
Remote Operation Offers Clinical Advantages
One of the LIBERTY System’s defining innovations is its remote operating capability.
Rather than standing directly beside the patient throughout the procedure, physicians can operate the robotic system from a protected workstation located within the procedure room.
This approach offers several potential advantages.
Reduced Radiation Exposure
Continuous fluoroscopic imaging exposes physicians and clinical staff to cumulative radiation over many years of practice.
Remote operation enables physicians to perform procedures from shielded workstations, potentially reducing occupational radiation exposure.
Less Physical Strain
Interventional physicians traditionally wear heavy lead aprons during procedures to protect against radiation.
These protective garments can contribute to chronic neck, shoulder, and back problems after years of repetitive use.
By allowing physicians to operate remotely, LIBERTY may help reduce the physical burden associated with wearing protective lead equipment throughout lengthy procedures.
Enhanced Precision
Robotic manipulation provides precise movement of guidewires and catheters within blood vessels.
Although physicians remain fully responsible for procedural decision-making, robotic assistance may improve control during delicate vascular navigation.
Single-Use Design Creates a New Category
Another distinguishing characteristic of the LIBERTY platform is its single-use robotic architecture.
Traditional robotic surgical systems often rely on reusable robotic components requiring sterilization, maintenance, and complex setup between procedures.
LIBERTY instead incorporates disposable robotic elements designed for individual procedures.
This design may simplify workflow while reducing maintenance requirements and minimizing concerns associated with reusable instrumentation.
The single-use approach also supports procedural standardization and may improve operational efficiency within catheterization laboratories and vascular intervention suites.
Microbot Medical believes this architecture represents a fundamentally different approach to robotic-assisted intervention.
Commercial Adoption Continues to Accelerate
Following its Full Market Release in early April, the LIBERTY System has experienced increasing commercial adoption throughout the United States.
According to the company, the robotic platform is now actively being utilized at several prominent academic medical centers located in:
- New York
- Pennsylvania
- Florida
- Georgia
- Massachusetts
- Michigan
- North Carolina
Expansion into leading academic institutions represents an important milestone because teaching hospitals often serve as early adopters of emerging medical technologies while helping establish clinical best practices.
Successful implementation at these centers may encourage broader adoption among community hospitals and vascular treatment facilities.
Growing utilization also provides physicians with additional opportunities to evaluate the system’s performance across diverse clinical settings.
Validation Beyond Regulatory Approval
Although FDA clearance established the LIBERTY System’s regulatory pathway into the U.S. market, industry recognition provides additional validation regarding its technological significance.
Awards recognizing innovation frequently acknowledge broader contributions beyond regulatory achievement alone.
In this case, Surgical Robotics Technology highlighted both the commercial progress and technological originality demonstrated by Microbot Medical.
According to Josef de Pfeiffer, CEO and Founder of Surgical Robotics Technology, Microbot Medical exemplifies the pioneering innovation that the Innovative Start-Up Award was designed to recognize.
He noted that the company has demonstrated strong commitment to advancing surgical robotics through technological excellence while maintaining a clear vision for the future of healthcare.
The organization congratulated the Microbot Medical team for developing a platform capable of expanding possibilities within robotic-assisted vascular intervention.
Leadership Reflects on the Achievement
Microbot Medical President, Chief Executive Officer, and Chairman Harel Gadot described the award as meaningful recognition of the company’s long-term innovation strategy.
He emphasized that the Surgical Robotics Industry Awards recognize organizations developing technologies capable of transforming healthcare through meaningful innovation.
According to Gadot, the LIBERTY System represents that vision by introducing a completely new approach to robotic-assisted peripheral endovascular procedures.
As the only FDA-cleared remotely operated single-use robotic system in its category, LIBERTY is helping redefine physician expectations regarding accessibility, efficiency, and procedural flexibility within vascular intervention.
Company leadership believes the platform establishes an entirely new segment within surgical robotics rather than competing directly with traditional multi-purpose robotic systems.
Built on a Vision of Accessibility
Microbot Medical’s development philosophy has consistently emphasized creating robotic technology that is practical and accessible rather than unnecessarily complex.
From the company’s earliest stages, engineers sought to challenge conventional assumptions surrounding robotic surgery.
Instead of designing larger and more expensive robotic platforms, Microbot Medical focused on producing a compact solution capable of integrating into existing clinical workflows while remaining easier to implement.
This philosophy has shaped both the physical design of the LIBERTY platform and its commercial strategy.
By simplifying robotic intervention, the company hopes to expand physician access while encouraging broader adoption across healthcare institutions.
Supporting the Future of Robotic Intervention
Robotic-assisted surgery continues to expand into new medical specialties beyond traditional laparoscopic procedures.
Interventional cardiology, vascular surgery, neurovascular intervention, and peripheral endovascular therapy increasingly represent important opportunities for robotic innovation.
As minimally invasive procedures become more technically sophisticated, robotic technologies may provide additional precision, procedural consistency, and ergonomic improvements.
Microbot Medical believes LIBERTY is positioned to play an important role in this evolving landscape by addressing physician needs specific to vascular intervention.
The company’s continued investment in commercialization and product development reflects confidence that robotic endovascular procedures will become increasingly common over the coming years.
Acknowledging Employees and Clinical Partners
Gadot also used the occasion to recognize the contributions of employees, physicians, clinical collaborators, shareholders, and supporters who have participated throughout the company’s development journey.
Developing novel medical technology requires close collaboration among engineers, clinicians, regulatory specialists, manufacturing teams, and healthcare providers.
The successful commercialization of LIBERTY reflects years of multidisciplinary collaboration focused on solving practical challenges encountered during vascular procedures.
Company leadership expressed appreciation for the dedication and confidence shown by everyone involved in bringing the technology from concept to commercial reality.
While celebrating the award, Microbot Medical emphasized that its primary focus remains continued commercial execution and broader clinical adoption.
The company plans to continue expanding the availability of the LIBERTY System across healthcare institutions while supporting physicians through education, training, and implementation programs.
Future priorities include increasing utilization among existing customers, expanding installations at additional hospitals and academic medical centers, and continuing innovation that enhances robotic-assisted endovascular care.
The company also intends to strengthen its commercial strategy while exploring opportunities to further advance the capabilities of the LIBERTY platform.
Advancing the Next Generation of Endovascular Care
Receiving the Innovative Start-Up Award at the 2026 Surgical Robotics Industry Awards represents a significant milestone for Microbot Medical as it continues building momentum within the rapidly growing surgical robotics market.
The recognition highlights not only the technological innovation behind the LIBERTY Endovascular Robotic System but also its growing clinical adoption following FDA clearance and commercial launch.
As hospitals increasingly seek technologies that improve procedural precision, reduce physician fatigue, minimize radiation exposure, and streamline minimally invasive interventions, platforms such as LIBERTY may play an increasingly important role in the future of vascular medicine.
With expanding adoption across leading academic medical centers, continued commercialization efforts, and recognition from one of the industry’s leading surgical robotics organizations, Microbot Medical is well positioned to continue advancing robotic-assisted endovascular care while helping shape the next generation of minimally invasive vascular intervention.
Source link: https://ir.microbotmedical.com/
